Hands-on HIPEC Course and Anatomy Lab

Publication of a randomized trial in the New England Journal of Medicine demonstrating that hyperthermic intraperitoneal chemotherapy (HIPEC) during interval cytoreduction in women with advanced ovarian cancer improves both progression-free and overall survival has sparked interest among centers that treat ovarian cancer. A number of centers are initiating HIPEC programs.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

June 21-22 course on HIPEC

If you are practicing at one of these centers or have interest in HIPEC, the fast-approaching “Hands-on HIPEC Course and Anatomy Lab” will be of interest. The course will take place June 21-22, 2018, at Cleveland Clinic.

Among largest HIPEC programs in U.S.

Cleveland Clinic Ob/Gyn & Women’s Health Institute, which managed more than 140 ovarian cancer surgical cases in 2017, has offered HIPEC to select patients with advanced and recurrent ovarian cancer for four years, under the leadership of gynecologic oncologist Robert DeBernardo, MD. Dr. DeBernardo, established the HIPEC program four years ago and has led it since. He is Director of Minimally Invasive Surgery for the institute and Director of the Peritoneal Surface Malignancy Program.

“Because of ongoing treatment challenges in ovarian cancer, we are encouraged by results from the latest clinical trial of HIPEC,” Dr. DeBernardo says. “Our hope is to share our experience and help newer programs understand which patients may benefit from HIPEC and how to safely administer this promising therapy.” HIPEC is only effective in patients who have minimal or no residual disease after surgery, he adds. With well over 100 patients treated, Cleveland Clinic has one of the country’s largest experiences using HIPEC for ovarian cancer.

The 1-1/2 day course will include these sections: